Sangyong Jon
Korea Advanced Institute of Science and Technology · 生化学・遺伝学・分子生物学
研究室紹介
Professor Sangyong Jon's research lab specializes in the design and development of advanced nanomaterials for targeted theranostics and drug delivery, with a strong focus on cancer and inflammatory diseases. The lab integrates nanotechnology, bioconjugation, and molecular targeting to create smart nanoparticles that enable simultaneous diagnosis (e.g., via MRI) and therapy (e.g., drug delivery or immunostimulation). Key innovations include aptamer-conjugated nanoparticles, PEGylated natural compound-based nanotherapeutics, and multifunctional platforms for imaging and immune modulation. The lab’s work emphasizes improving the solubility, stability, and bioavailability of bioactive molecules while ensuring high specificity and efficacy in preclinical models.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15We report a novel quantum dot (QD)-aptamer(Apt)-doxorubicin (Dox) conjugate [QD-Apt(Dox)] as a targeted cancer imaging, therapy, and sensing system. By functionalizing the surface of fluorescent QD with the A10 RNA aptamer, which recognizes the extracellular domain of the prostate specific membrane antigen (PSMA), we developed a targeted QD imaging system (QD-Apt) that is capable of differential uptake and imaging of prostate cancer cells that express the PSMA protein. The intercalation of Dox,
Computed tomography (CT) is one of the most useful diagnostic tools among commonly used biomedical imaging techniques, which also include magnetic resonance imaging (MRI), positron emission tomography (PET), and ultrasound. However, currently available CT contrast agents, which are based on small iodinated molecules, possess a number of limitations, including a lack of targeted molecular imaging, short imaging time, and renal toxicity. Here, we report a multifunctional nanoparticle for targeted
Trojan aptamer: A novel strategy for targeted drug delivery to cancer cells was developed through the formation of a physical conjugate (see scheme) between doxorubicin (Dox) and the A10 RNA aptamer that binds to the prostate-specific membrane antigen (PSMA). The aptamer–Dox conjugate could efficiently bind to PSMA-expressing cells, thereby resulting in its uptake and the intracellular release of Dox.
Advances in genetic engineering tools have contributed to the development of strategies for utilizing biologically derived vesicles as nanomedicines for achieving cell-specific drug delivery. Here, we describe bioengineered bacterial outer membrane vesicles (OMVs) with low immunogenicity that can target and kill cancer cells in a cell-specific manner by delivering small interfering RNA (siRNA) targeting kinesin spindle protein (KSP). A mutant Escherichia coli strain that exhibits reduced endotox
Despite the high potency of bilirubin as an endogenous anti-inflammatory compound, its clinical translation has been hampered because of its insolubility in water. Bilirubin-based nanoparticles that may overcome this critical issue are presented. A polyethylene glycol compound (PEG) was covalently attached to bilirubin, yielding PEGylated bilirubin (PEG-BR). The PEG-BR self-assembled into nanoscale particles with a size of approximately 110 nm, termed bilirubin nanoparticles (BRNPs). BRNPs are h
CG-rich duplex containing prostate-specific membrane antigen (PSMA) aptamer-conjugated thermally cross-linked superparamagnetic iron oxide nanoparticles (TCL-SPIONs) is reported as prostate cancer-specific nanotheranostic agents. These agents are capable of prostate tumor detection in vivo by magnetic resonance imaging (MRI) and selective delivery of drugs to the tumor tissue, simultaneously. The prepared PSMA-functionalized TCL-SPION via a hybridization method (Apt-hybr-TCL-SPION) exhibited pre
Rosmarinic acid (RA), one of the most important polyphenol-based antioxidants, has received growing interest because of its bioactive properties, including anti-inflammatory, anticancer, and antibacterial activities. Despite the high therapeutic potential of RA, its intrinsic properties of poor water solubility and low bioavailability have limited its translation into the clinic. Here, we report on the synthesis and preparation of PEGylated RA-derived nanoparticles (RANPs) and their use as a the
Delivery tracking: Goldnanoparticles (AuNPs) were functionalized with a red fluorescent protein (RFP, pink shapes in picture) as model antigen and an oligonucleotide (CpG) that stimulates the immune response. These functionalized AuNPs were used as cancer vaccines in a tumor model, where they enabled efficient delivery of an antigen to target sites, tracking of the vaccines using noninvasive clinical imaging, and cancer prevention and therapy. Vaccination with the aid of adjuvants is a highly ef
A new platform for oral delivery of paclitaxel (PTX) was developed through chemical conjugation of PTX to a low molecular weight chitosan (LMWC). The LMWC-PTX conjugate contained approximately 12 wt % PTX and showed greatly enhanced water solubility (>1 mg/mL) as compared to native PTX. The conjugate showed comparable IC 50 values to that of the parent PTX against human cancer cell lines. The pharmacokinetic data revealed approximately 42% of bioavailability after oral administration of 5 mg PTX
The synthesis of a poly(ethylene glycol) (PEG)-grafted surface-reactive random copolymer and its self-assembled structure on Si/SiO 2 substrates for construction of nonbiofouling surfaces are reported. The copolymer, poly(TMSMA-r-PEGMA), which is comprised of an “anchor part” (trimethoxysilane) and a “function part” (PEG), was synthesized by a radical polymerization reaction. The copolymer spontaneously formed monolayers on Si/SiO 2 wafers with average thicknesses of 11 Å. Tapping mode atomic fo
We report a novel platform for intracellular delivery of genetic material and nanoparticles, based on vertically aligned carbon nanosyringe arrays (CNSAs) of controllable height. Using this technology, we have shown that plasmid and quantum dots can be efficiently delivered to the cytoplasm of cancer cells and human mesenchymal stem cells. The CNSA platform holds great promise for a myriad of applications including cell-based therapy, imaging, and tracking in vivo, and in biological studies aime